Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1 Neoplasms 1

Interventions

pembrolizumab 40 Carboplatin 35 Cisplatin 31 Paclitaxel 25 Nivolumab 22 Pemetrexed 21 Gemcitabine 20 Dexamethasone 19 Ipilimumab 16 Rituximab 16 Cyclophosphamide 14 Fluorouracil 12 Lenalidomide 12 Docetaxel 11 atezolizumab 11 Bevacizumab 10 Capecitabine 10 Cytarabine 10 Prednisone 10 daratumumab 10 durvalumab 10 trastuzumab deruxtecan 10 Bortezomib 9 olaparib 9 130-nm albumin-bound paclitaxel 8 Leucovorin 8 Trastuzumab 8 Crizotinib 7 Daunorubicin 7 Doxorubicin 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡